deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT03239470

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)

Sponsor: Autoimmunity Centers of Excellence

Conditions Pemphigus Foliaceus Pemphigus Vulgaris
Interventions Cohort 1: 1.0 x 10^8 PolyTregs Cohort 2: 2.5x10^8 PolyTregs
Updated 16 times since 2017 Last updated: Feb 14, 2024 Started: Oct 10, 2017 Primary completion: Dec 10, 2020 Completion: Jan 9, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of recruitment, ongoing and new feasibility issues, and the impact of the coronavirus infectious disease 19 (COVID-19) pandemic

Other terminated trials from Autoimmunity Centers of Excellence

See all terminations from Autoimmunity Centers of Excellence

A PHASE1 clinical study on Pemphigus Foliaceus and Pemphigus Vulgaris, this trial is terminated or withdrawn. The trial is conducted by Autoimmunity Centers of Excellence and has accumulated 16 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Aug 2019 · 11 months · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~Nov 2022 · 11 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Mar 2024 · 11 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Mar 2024 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Apr 2023 — Mar 2024 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  5. Mar 2023 — Apr 2023 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Nov 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Dec 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2021 — Dec 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Aug 2019 — Aug 2020 [monthly]

    Recruiting PHASE1

  7. Sep 2018 — Aug 2019 [monthly]

    Recruiting PHASE1

  8. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  10. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Aug 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Autoimmunity Centers of Excellence
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Rho Federal Systems Division, Inc.
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations